Crinetics supplements proxy disclosures amid shareholder lawsuits over Vertex merger

Crinetics Pharmaceuticals, Inc.

Three shareholder lawsuits filed Aug 6 & 17, 2026 in NY and CA allege misleading proxy disclosures; seek to block merger.
Board unanimously reaffirms 'FOR' recommendation on merger and related proposals; special shareholder meeting set for Aug 28, 2026.
Supplemental disclosures add J.P. Morgan and Leerink valuation analyses; updated projections show revenue rising to $1,057M by 2030E and $4,583M by 2035E.
Advisor fees disclosed: J.P. Morgan ~$69.4M and Leerink ~$60.8M, largely contingent on $85.00/share deal closing.
Company denies allegations, says proxy complies with law; voluntary supplements made to avoid nuisance and potential delays.

Featured in Daily 8-K Digest

Selected #2 for 2026-08-19. Read digest

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.